Onkologie. 2012:6(1):37-39

Drug-induced hallucinatory syndrome in a female patient with breast cancer

Ladislav Slováček1, Birgita Slováčková2
1 Klinika onkologie a radioterapie, FN a LF UK v Hradci Králové
2 Psychiatrická klinika, FN a LF UK v Hradci Králové

The authors report on a case of drug-induced hallucinatory syndrome after paclitaxel infusion in a 42-year-old woman with breast

carcinoma treated with adjuvant chemotherapy AC-T. This case report highlights the potential risk of paclitaxel causing hallucinatory

syndrome. At the same time it indicates the need to cooperate with the psychiatrist. Early symptomatic psychopharmacological treatment

enabled the smooth completion of chemotherapy.

Keywords: breast carcinoma, chemotherapy, paclitaxel, psychotropic side effects

Published: February 29, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slováček L, Slováčková B. Drug-induced hallucinatory syndrome in a female patient with breast cancer. Onkologie. 2012;6(1):37-39.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Přibylová M, Dvořáková M, Vaněk T. Deriváty paklitaxelu pro cílený transport cytostatika. Chem Listy 2010; 104: 1023-1028.
    2. Adam Z, Vorlíček J, Sedláčková Š. Přehled protinádorové farmakologické léčby. Praktické Lékárenství 2005; 2: 76-80.
    3. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol. the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646-662.
    4. Spencer MC, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 795-845. Go to original source...
    5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 22: 665-667. Go to original source... Go to PubMed...
    6. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999; 57: 1215-1221. Go to original source...
    7. Aoudjit F, Vuori K. Integrin signalling inhibits paclitaxelinduced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995-5004. Go to original source... Go to PubMed...
    8. Monsarrat B, Royer I, Wright M, Cresteil T. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull Cancer 1997; 84: 125-133.
    9. Monsarrat B, Chtelut E, Royer I, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998; 26: 229-233.
    10. Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996; 46: 1596-1599. Go to original source... Go to PubMed...
    11. Krombholz R. Farmakologicky navozené deprese. Psychiat Pro Praxi 2008; 9: 209-212.
    12. Herman E, Praško J, Seifertová D, et al. Konziliární psychiatrie, Medical Tribune CZ, Praha, Galén 2007.
    13. Zapletalová O. Neurologické komplikace protinádorové léčby. Neurol Pro Praxi 2003; 5: 249-252.
    14. Ustohal L, Češková E, Přikryl R. Augmentace antidepresiv antipsychotiky. Psychiatr praxi 2011; 12: 98-99.
    15. Švestka J. Nová psychofarmaka: antipsychotikum quetiapin. Psychiatrie 2000; 2: 120-133.
    16. Nelson JC. Adjunctive Atypical Antipsychotics in Medication-Resistant Depression. CNS Spectr 2010; 15: 10-13. Go to original source... Go to PubMed...
    17. Ziske CG, Schottker B, Gorschluter M, Mey U, Kleinschimidt R, Schlegel U. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 2002; 13: 629-631. Go to original source... Go to PubMed...
    18. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Baron A, Jones RB. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999; 5: 501-506.
    19. Webster LK, Crinis NA, Morton CG, Millward MJ. Plasma alcohol concentrations in patients following paclitaxel infusion. Cancer Chemother Pharmocol 1996; 37: 499-501. Go to original source... Go to PubMed...
    20. Chen YM, Tsai CM, Perng RP. Reversible hepatic coma possibly induced by docetaxel treatment. Lung Cancer 2001; 31: 347-348. Go to original source... Go to PubMed...
    21. Guglani S, Farrugia D, Elsdon M, Parmar M, Owen JR. Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel. Clin Oncol 2003; 15: 160-161. Go to original source... Go to PubMed...
    22. Cher L. Neurologic complications of cancer chemotherapy. Cancer Forum 2004; 28: 18-19.
    23. Nicolao P, Giommeto B. Neurological toxicity of ifosfamid. Oncology 2003; 65: S11-16. Go to original source... Go to PubMed...
    24. Pelgrims J. Methylene blue in the treatment and prevention of ifosfamid-induced encephalopathy: Report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-294. Go to original source... Go to PubMed...
    25. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and neurotoxic mechanisms of ifosfamid encephalopathy. Eur J Clin Pharmacol 1996; 50: 249-252. Go to original source... Go to PubMed...
    26. Johnston PG, Spence RAJ. Oncologic emergencies. Oxford University Press. 2002.
    27. Bourque F, Karama S, Looper K, et al. Acute Tamoxifen-Induced Depression and Its Prevention with Venlafaxine. Psychosomatics 2009; 50: 162-165. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.